CRDF vs CSPI Comparison

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.